๎๊ฒ์
๎๊ฒ์
๎
Inhibikase Therapeutics Inc
IKT๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
1.730USD
-0.130-6.99%
์ข
๊ฐย 05/15, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
228.42M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Inhibikase Therapeutics Inc ํ์ฌ
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Companyโs multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ IKT
ํ์ฌ ์ด๋ฆInhibikase Therapeutics Inc
์์ฅ์ผDec 23, 2020
CEOIwicki (Mark T)
์ง์ ์15
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 23
์ฃผ์1000 N. West Street, Suite 1200
๋์WILMINGTON
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ19801
์ ํ13022953800
์น์ฌ์ดํธhttps://www.inhibikase.com/
์ข
๋ชฉ ์ฝ๋ IKT
์์ฅ์ผDec 23, 2020
CEOIwicki (Mark T)
Inhibikase Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
--
-100.00%
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, May 10
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, May 10
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Sands Capital Ventures LLC
9.86%
Soleus Capital Management, L.P.
8.24%
Fairmount Funds Management LLC
6.53%
Adar1 Capital Management LLC
6.11%
Trails Edge Capital Partners LP
4.68%
๊ธฐํ
64.58%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Sands Capital Ventures LLC
9.86%
Soleus Capital Management, L.P.
8.24%
Fairmount Funds Management LLC
6.53%
Adar1 Capital Management LLC
6.11%
Trails Edge Capital Partners LP
4.68%
๊ธฐํ
64.58%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Hedge Fund
43.67%
Investment Advisor
20.91%
Investment Advisor/Hedge Fund
9.78%
Corporation
4.42%
Private Equity
4.11%
Individual Investor
2.00%
Research Firm
0.40%
Bank and Trust
0.07%
Pension Fund
0.04%
๊ธฐํ
14.61%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2026Q1
152
103.21M
78.17%
+43.85M
2025Q4
122
64.55M
53.39%
+6.52M
2025Q3
110
54.77M
73.50%
+878.44K
2025Q2
87
62.36M
83.88%
+6.72M
2025Q1
82
60.21M
81.40%
+7.53M
2024Q4
61
58.78M
83.36%
+15.59M
2024Q3
38
1.99M
24.34%
-203.16K
2024Q2
42
2.13M
28.26%
+379.22K
2024Q1
47
1.51M
21.65%
-625.47K
2023Q4
49
1.53M
25.68%
-638.36K
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Sands Capital Ventures LLC
13.02M
9.86%
--
--
Dec 31, 2025
Soleus Capital Management, L.P.
10.88M
8.24%
+4.55M
+71.94%
Dec 31, 2025
Fairmount Funds Management LLC
8.63M
6.53%
+2.50M
+40.82%
Dec 31, 2025
Adar1 Capital Management LLC
8.06M
6.11%
+2.82M
+53.67%
Dec 31, 2025
Trails Edge Capital Partners LP
6.18M
4.68%
+6.18M
--
Dec 31, 2025
Blackstone Alternative Asset Management, L.P.
5.94M
4.5%
+3.30M
+125.08%
Dec 31, 2025
Invus Public Equities Advisors, LLC
5.85M
4.43%
+5.85M
--
Dec 31, 2025
SP IKT Holdings LLC
5.84M
4.42%
--
--
Mar 16, 2026
Perceptive Advisors LLC
5.42M
4.11%
--
--
Dec 31, 2025
Commodore Capital LP
5.40M
4.09%
--
--
Dec 31, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
๋น์จ0.02%
iShares Russell 2000 Value ETF
๋น์จ0.01%
ProShares Hedge Replication ETF
๋น์จ0%
iShares Russell 2000 ETF
๋น์จ0%
iShares Russell 2000 Growth ETF
๋น์จ0%
Global X Russell 2000 ETF
๋น์จ0%
Proshares Ultra Russell 2000
๋น์จ0%
ProShares UltraPro Russell2000
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
Jun 29, 2023
Merger
6โ1
Jun 29, 2023
Merger
6โ1
Jun 29, 2023
Merger
6โ1
Jun 29, 2023
Merger
6โ1
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
Jun 29, 2023
Merger
6โ1
Jun 29, 2023
Merger
6โ1
Jun 29, 2023
Merger
6โ1
Jun 29, 2023
Merger
6โ1
